# Maintenance of Efficacy.

> **NCT00796601** · PHASE3 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** Esreboxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00796601
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-05-01
- **Primary completion:** 2010-05-01
- **Final completion:** 2010-11-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796601, "Maintenance of Efficacy.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00796601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*